Search - tctmd.com

Displaying 1 - 20 of 126

Sort: Relevancy | Date

Presentation THT 2026

Serial Echocardiography After Greater Splanchnic Nerve Ablation In Hfpef Demonstrates Reductions In LV Filling Pressures In Clinical Responders But Not In Nonresponders: 12 Month Follow Up In The REBALANCE-HF Trial

Presenter: Sheldon E. Litwin

March 04, 2026

Presentation THT 2026

Appraising the Risk of Harm in HFpEF and the Likelihood of Benefit in HFrEF

Presenter: Sheldon E. Litwin

March 04, 2026

Presentation THT 2026

Managing Afib: Is There a Difference in HFpEF vs HFrEF

Presenter: Nassir F. Marrouche

March 03, 2026

Presentation THT 2026

Percutaneous Pericardiotomy as a Treatment for HFpEF (Heart Failure Solutions)

Presenter: Barry Borlaug

March 03, 2026

Presentation THT 2026

Levosimendan: Mechanisms and Clinical Effects as a Treatment for PH-HFpEF

Presenter: Sanjiv J. Shah

March 03, 2026

Presentation THT 2026

Ultrasound Pulmonary Artery Denervation as a Treatment for Heart Failure (Gradient Medical)

Presenter: Alex Rothman

March 03, 2026

Presentation THT 2026

Radiofrequency Pulmonary Artery Denervation for Heart Failure (Pulnovo)

Presenter: Giora Weisz

March 03, 2026

Presentation THT 2026

Splanchnic Nerve Ablation for Treatment of HF Across the Spectrum of LV EFs

Presenter: Parag Goyal

March 03, 2026

Presentation THT 2026

Renal Denervation Beyond HTN: Implications and the Intersection Between Heart Failure and Fatty Liver

Presenter: David E. Kandzari

March 03, 2026

Presentation THT 2026

The Role of the Myocardium in HFpEF

Presenter: Michael R. Zile

March 03, 2026

Presentation THT 2026

Perctuaneous Pericardiotomy - Preliminary Findings from the PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF)

Presenter: Ammar M. Killu

March 03, 2026

Presentation THT 2026

Atrio-Ventricular Interval Modulation (AVIM) for HFpEF

Presenter: David E. Kandzari

March 03, 2026

Presentation THT 2026

Incidence of HF Therapy Escalation and Time-to-Clinical Worsening in Atrial Shunt- vs. Sham-Treated Patients with HFpEF/HFmrEF During 5-Year Follow-Up: REDUCE LAP-HF II Trial

Presenter: Grant Reed

March 03, 2026

Presentation THT 2026

Antagonist: Deep Phenotyping and Phenomapping Has Been and Will Continue to Be A Mirage in Understanding the Mechanisms and Tailoring Treatment for HFpEF.

Presenter: Milton Packer

March 02, 2026

Presentation THT 2026

Protagonist: HFpEF is Highly Heterogeneous, Requiring a Multimodal Precision Medicine Approach for True Progress.

Presenter: Sanjiv J. Shah

March 02, 2026

Presentation THT 2026

The Role of the Heart in HFpEF

Presenter: Javed Butler

March 02, 2026

Presentation THT 2026

What Causes Inflammation in HFpEF? What Lights the Fire?

Presenter: Mark C. Petrie

March 02, 2026

Presentation THT 2026

The Cardio-Hematopoietic Axis in HFpEF: A Theory of Everything

Presenter: Douglas L. Mann

March 02, 2026

Presentation THT 2026

The Adipokine Hypothesis of HFpEF: A New Unifying Framework

Presenter: Milton Packer

March 02, 2026

Presentation THT 2026

Role of Obesity and Adiposity in HFpEF: Fat Is Where It Is At

Presenter: Barry Borlaug

March 02, 2026

Advertisement

Serial Echocardiography After Greater Splanchnic Nerve Ablation In Hfpef Demonstrates Reductions In LV Filling Pressures In Clinical Responders But Not In Nonresponders: 12 Month Follow Up In The REBALANCE-HF Trial

Appraising the Risk of Harm in HFpEF and the Likelihood of Benefit in HFrEF

Managing Afib: Is There a Difference in HFpEF vs HFrEF

Percutaneous Pericardiotomy as a Treatment for HFpEF (Heart Failure Solutions)

Levosimendan: Mechanisms and Clinical Effects as a Treatment for PH-HFpEF

Ultrasound Pulmonary Artery Denervation as a Treatment for Heart Failure (Gradient Medical)

Radiofrequency Pulmonary Artery Denervation for Heart Failure (Pulnovo)

Splanchnic Nerve Ablation for Treatment of HF Across the Spectrum of LV EFs

Renal Denervation Beyond HTN: Implications and the Intersection Between Heart Failure and Fatty Liver

The Role of the Myocardium in HFpEF

Perctuaneous Pericardiotomy - Preliminary Findings from the PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF)

Atrio-Ventricular Interval Modulation (AVIM) for HFpEF

Incidence of HF Therapy Escalation and Time-to-Clinical Worsening in Atrial Shunt- vs. Sham-Treated Patients with HFpEF/HFmrEF During 5-Year Follow-Up: REDUCE LAP-HF II Trial

Antagonist: Deep Phenotyping and Phenomapping Has Been and Will Continue to Be A Mirage in Understanding the Mechanisms and Tailoring Treatment for HFpEF.

Protagonist: HFpEF is Highly Heterogeneous, Requiring a Multimodal Precision Medicine Approach for True Progress.

The Role of the Heart in HFpEF

What Causes Inflammation in HFpEF? What Lights the Fire?

The Cardio-Hematopoietic Axis in HFpEF: A Theory of Everything

The Adipokine Hypothesis of HFpEF: A New Unifying Framework

Role of Obesity and Adiposity in HFpEF: Fat Is Where It Is At

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content